Check out our free and informative ezines and sign up now
Biolase Technology will need to address its compliance process after the FDA issued the firm a recent warning letter for auditing system lapses as well as software and delivery problems.
This article is viewable by subscribers only. To view this article, please select an option below.
ePublishing :: CMS, Hosting & Web Development | © Copyright